Evidence map›Paper›PMID 39786526›Full record

ArticleBiochemical genetics2026

Status of IKZF1 Deletions in Diagnose and Relapsed Pediatric B-ALL Patients.

Yücel Erbilgin, Sinem Firtina, Elif Kirat, Khusan Khodzhaev, Zeynep Karakas, Ayşegül Ünüvar, Süheyla Ocak, Tülin Tiraje Celkan, Emine Zengin, Sema Aylan Gelen and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yücel ErbilginDepartment of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Topkapı mh, Gureba Hastanesi Cd. No:69, 34093, Fatih, Istanbul, Turkey. yucel.erbilgin@istanbul.edu.tr.ORCID http://orcid.org/0000-0001-6969-6649
Sinem FirtinaDepartment of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Topkapı mh, Gureba Hastanesi Cd. No:69, 34093, Fatih, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-3370-8545
Elif KiratDepartment of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Topkapı mh, Gureba Hastanesi Cd. No:69, 34093, Fatih, Istanbul, Turkey.
Khusan KhodzhaevDepartment of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Topkapı mh, Gureba Hastanesi Cd. No:69, 34093, Fatih, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-8008-7553
Zeynep KarakasPediatric Hematology Oncology Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-8835-3235
Ayşegül ÜnüvarPediatric Hematology Oncology Department, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-4730-7697
Süheyla OcakDivision of Pediatric Hematology Oncology, Department of Pediatrics, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-7479-7444
Tülin Tiraje CelkanDivision of Pediatric Hematology Oncology, Department of Pediatrics, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-7287-1276
Emine ZenginDepartment of Pediatric Hematology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.ORCID http://orcid.org/0000-0002-7362-6130
Sema Aylan GelenDepartment of Pediatric Hematology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.ORCID http://orcid.org/0000-0002-8473-8146
Zeynep Yildiz YildirmakPediatric Hematology Division, Ministry of Health Sisli Etfal Education and Research Hospital, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-3939-2761
Ozlem TolukDepartment of Biostatistics and Medical Informatics, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-6495-0839
Ozden Hatirnaz NgDepartment of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Topkapı mh, Gureba Hastanesi Cd. No:69, 34093, Fatih, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-7728-6527
Ugur OzbekDepartment of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Topkapı mh, Gureba Hastanesi Cd. No:69, 34093, Fatih, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-5319-0547
Müge SayitogluDepartment of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Topkapı mh, Gureba Hastanesi Cd. No:69, 34093, Fatih, Istanbul, Turkey. mugeay@istanbul.edu.tr.ORCID http://orcid.org/0000-0002-8648-213X

Funding

Research Fund of Istanbul University 35624The Scientific and Technological Research Council of Türkiye 114S038
6 · The paper itself

Abstract

IKZF1 deletions (ΔIKZF1) are common in precursor B-cell acute lymphoblastic leukemia (B-ALL) and are assumed to have a prognostic impact. We aimed to determine the prognostic implications of ΔIKZF1 and CRLF2 overexpression in pediatric B-ALL. Furthermore, we sought to compare the multiplex polymerase chain reaction (PCR) assay with standard multiplex ligand-dependent probe amplification (MLPA) methods to ascertain IKZF1 status in a clinical context. Seventy-nine diagnoses and 43 relapse B-ALL samples were evaluated for deletions of IKZF1 Δ2-7, Δ4-7, and Δ4-8 by conventional PCR and then sequenced by targeted sequencing. Subsequently, MLPA analysis was performed for ΔIKZF1 detection, and CRLF2 expression was evaluated in 42 diagnose time B-ALL patients by QRT-PCR. ΔIKZF1 was detected in 10 out of 79 diagnose samples (12.66%) and eight of the 43 first relapsed materials (18.60%). Our results revealed no association between survival outcomes with ΔIKZF1 or CRLF2 overexpression status in pediatric B-ALL patients. However, we found ΔIKZF1 was more frequent among relapsed samples, and the deletions showed consistency between diagnose-first/second relapse pairs of samples. These results suggest that ΔIKZF1 may contribute to the development of treatment failure in B-ALL. Furthermore, we demonstrated methodological adjustments in conventional PCR and MLPA for selected alterations in ΔIKZF1.

Indexed as

Gene DeletionIkaros Transcription FactorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleHumansInfantMalePrognosisReceptors, CytokineRecurrenceCRLF2 protein, humanIkaros Transcription FactorIKZF1 protein, humanReceptors, CytokineB-ALLCRLF2IKZF1Prognosis

Identifiers

PMID39786526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.